Flagship Zilretta Zilretta is Flexion's lead local therapy for osteoarthritis knee pain, delivering extended-release triamcinolone via intra-articular injection. Its non-opioid profile and extended duration support adoption in orthopedic and pain-management settings; prioritize payer engagement and clinician education to expand uptake.

Acquisition Signals Publicized talks with Sanofi and Pacira's eventual acquisition signal strong buyer interest in Flexion's lead asset. Explore licensing, co-development, or distribution partnerships with large pharma or the acquirer’s network to scale commercialization.

Channel Expansion With a lean team, there is room to broaden geographic and clinic coverage. Consider partnerships with distributors or contract sales organizations to reach orthopedic surgeons, pain specialists, and hospital outpatient clinics.

Non-Opioid Edge Zilretta's non-opioid, extended-release profile differentiates it in pain management and may improve payer access. Position as a safer alternative to opioids in value-based conversations.

Advocacy Partnerships Collaboration with patient communities and sports-related groups suggests potential for advocacy-driven awareness programs. Leverage KOLs, patient groups, and clinical champions to accelerate launches and payer discussions.